Pharvaris N.V. (PHVS) has disclosed a new risk, in the Innovation / R&D category.
Pharvaris N.V. faces significant business risk as it navigates the development and potential commercialization of its product candidates, PHVS416 and PHVS719, without any current marketable products. The company’s success hinges on obtaining regulatory approvals and demonstrating the efficacy and safety of its treatments through costly and time-consuming clinical trials. With no head-to-head clinical trial data comparing its candidates to existing treatments, the ability to market the products effectively, even if approved, remains uncertain. Moreover, failure to gain regulatory approval will prevent Pharvaris from commercializing these potential products, materially impacting its financial and operational prospects.
The average PHVS stock price target is $33.80, implying 51.50% upside potential.
To learn more about Pharvaris N.V.’s risk factors, click here.
